Skip To Main Content
Janssen-Cilag Poland on Muck Rack

Janssen-Cilag Poland

As seen in: Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Janssen-Cilag

Contact Janssen-Cilag, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A UK ANALYSIS OF THE DIFFERENTIAL DRUG COSTS PER 1% POINT DECREASE IN HBA1C AMONG ANTIHYPERGLYCEMIC AGENTS THAT INHIBIT SGLT2

|
By M. Schroeder, Janssen-Cilag UK, E. Chan, A. Schubert, Janssen-Cilag Poland
| Value in Health Journal Verified
In the seminal UK Prospective Diabetes Study, a 1% reduction in HbA1c was associated with important risk reductions in any diabetes-related end point, diabetes-related deaths, myocardial infarction, and microvascular complications. Here, we examine the drug cost of canagliflozin 100 and 300mg, dapagliflozin 10mg, and empagliflozin 10 and 25mg per a 1% reduction in HbA1c.
Open in Who Shared Issue with article?
See all 1 articles